Protagenic Therapeutics, Inc. has entered into a Securities Purchase Agreement with accredited investors to raise gross proceeds of approximately $1.5 million. The private placement, which closed on November 17, 2026, involves the issuance of 2,459,014 shares of common stock and accompanying warrants. The shares were sold at a price of $0.61 per share, calculated as 90% of the volume-weighted average price of the company's stock over the 30 trading days prior to the agreement.

The offering includes two series of warrants: Series A warrants with an exercise price of $0.67 per share and Series B warrants with an exercise price of $0.73 per share. Both warrant series are exercisable for cash only and expire under specific conditions, including the fifth anniversary of issuance or 30 days following the public disclosure of dosing the tenth patient in a Phase 1/2a clinical trial for PT00114 in Generalized Anxiety Disorder.

Brookline Capital Markets, a division of Arcadia Securities, LLC, served as the placement agent. The company agreed to pay a cash fee equal to 7.0% of the gross proceeds and a non-accountable expense allowance of 1.0% of the gross proceeds. Additionally, the placement agent received warrants equivalent to 7.0% of the total warrants issued to investors.

Protagenic intends to use the net proceeds for general corporate purposes, including product development, clinical programs, and operating expenses. The company also plans to file a registration statement with the SEC within 45 days to allow for the resale of the securities sold in the offering.

In related news, the company announced that it has incorporated feedback from the U.S. Food and Drug Administration (FDA) into its Chemistry, Manufacturing, and Controls (CMC) work for PT00114. The company has finalized the Phase 1/2a study design, which will include ascending-dose cohorts to evaluate safety and tolerability, followed by a cohort of patients with Generalized Anxiety Disorder to assess exploratory efficacy measures. First patient dosing is targeted for the second quarter of 2027, with topline safety data expected in the second half of 2027 and exploratory efficacy data in the first half of 2028.